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NIST  standard  reference  material  (SRM)  2373  was  developed  to improve  the  measurements  of the  HER2
gene ampliﬁcation  in DNA  samples.  SRM  2373  consists  of  genomic  DNA  extracted  from  ﬁve breast  cancer
cell  lines  with  different  amounts  of ampliﬁcation  of  the  HER2  gene.  The  ﬁve components  are  derived
from  the  human  cell  lines  SK-BR-3,  MDA-MB-231,  MDA-MB-361,  MDA-MB-453,  and  BT-474.  The  certiﬁed
values  are  the ratios of the  HER2  gene  copy  numbers  to the  copy  numbers  of selected  reference  genes
DCK,  EIF5B,  RPS27A,  and  PMM1.  The  ratios  were  measured  using  quantitative  polymerase  chain  reactionancer
eference material
alibrator
ucleic acid
ER2
igital PCR
and  digital  PCR,  methods  that gave  similar  ratios.  The  ﬁve  components  of SRM  2373  have  certiﬁed  HER2
ampliﬁcation  ratios  that  range  from  1.3  to 17.7.  The  stability  and  homogeneity  of the  reference  materials
were  shown  by  repeated  measurements  over  a  period  of several  years.  SRM  2373  is  a well  characterized
genomic  DNA  reference  material  that  can be used  to  improve  the  conﬁdence  of the  measurements  of
HER2  gene  copy number.
Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://. Introduction
The human epidermal growth factor receptor 2 (HER2, ofﬁcial
ymbol ERBB2)  is a proto-oncogene protein, a 185-kDa transmem-
rane glycoprotein with tyrosine kinase activity [1]. Ampliﬁcations
f the HER2 gene, resulting in protein overexpression, are present in
pproximately 20% of breast cancers, and have been associated with
oor patient prognosis [2,3]. The most common methods for HER2
easurements in clinical laboratories are the detection of protein
verexpression by immunohistochemistry (IHC) and the evalua-
ion of gene ampliﬁcation by in situ hybridization (ISH) methods.
 number of studies have reported problems with the accuracy
nd the concordance of the results obtained from different labo-
atories using IHC and ﬂuorescence ISH (FISH) methods [4,5]. The
merican Society of Clinical Oncology and the College of American
athologists published guidelines to improve the performance of
ER2 testing by IHC and ISH methods in 2007, and an update in
013 [6,7]. However, standardization of both IHC and ISH methods
∗ Corresponding author. Fax: +1 301 330 3447.
E-mail address: Kenneth.Cole@nist.gov (K.D. Cole).
ttp://dx.doi.org/10.1016/j.bdq.2016.02.001
214-7535/Published by Elsevier GmbH. This is an open access article under the CC BY-Ncreativecommons.org/licenses/by-nc-nd/4.0/).
across laboratories remains a major challenge. Approximately 20%
of HER2 testing performed may  be inaccurate [8].
Recently, genomic analytical methods have been developed that
enable DNA copy number variations (CNV) to be measured with
high sensitivity and speciﬁcity. As few as 50 cells extracted from
archival formalin-ﬁxed parafﬁn-embedded (FFPE) tissues may  be
quantiﬁed using quantitative PCR (qPCR) [9,10]. The results from
qPCR of HER2 measurements have been positively correlated with
the results from IHC and FISH analysis [10–13]. Koudelakova et al.
compared qPCR to IHC and FISH data in breast cancer samples,
and found that high sensitivity and speciﬁcity of the new method
was achieved and the results obtained with the qPCR method and
FISH/IHC agreed [14]. Digital PCR (dPCR) was used to measure
HER2 copy number in FFPE breast cancer tissue and these results
agreed with the results from FISH and IHC analysis [15]. Garcia-
Murillas used dPCR to measure the gene copy ratio of HER2 to
reference genes in the microdissected DNA from HER2 ampliﬁed
and HER2 non-ampliﬁed cancers. They too, obtained high sen-
sitivity and speciﬁcity and good agreement with the traditional
detection methods [16].
Many cancer cells, including these breast cancer cell lines, have
highly abnormal karyotypes, with multiple chromosome copies
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
PCR assays gene locations and primers used for certiﬁcation values.
Primer name Sequence PCR amplicon Location (GRCh37/hq19 nucleotide number)
HER2-2F CTCATCGCTCACAACCAAGT 112 bp Exon 7 (chr17:37864601–37864620)
HER2-2R GGTCTCCATTGTCTAGCACG (chr17:37864693–37864712)
EIF5B-F GGCCGATAAATTTTTGGAAATG 112 bp Intron 1 (chr2:99974140–99974161)
EIF5B-R GGAGTATCCCCAAAGGCATCT (chr2:99974231–99974251)
RPS27A-F CGGGTTTGGGTTCAGGTCTT 97 bp Intron 4 (chr2:55462316–55462335)
RPS27A-R TGCTACAATGAAAACATTCAGAAGTCT (chr2:55462386–55462412)
DCK-F  CTCAGAAAAATGGTGGGAATGTT 122 bp Exon 3 (chr4:71888097–71888119)
DCK-R GCCATTCAGAGAGGCAAGCT (chr4:71888199–71888218)
PMM1-F AGGTCTGGTGGCTTCTCCAAT 78 bp Intron 7 (chr22:41973739–41973759)
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: forward primer; R: reverse primer.
nd major structural changes [17]. The selection of the reference
enes is important in cancer cells because of the frequent gene
utations and gains or losses of DNA that have occurred. Chromo-
omal alterations in 15 breast cancer cell lines detected frequent
ains at 1q, 8q, 20q, 7, 11q, 13, 17q, 9q and 16p and frequent losses
t 8p, 11q14-qter, 18q and Xq [18]. Spectral karyotyping (SKY) using
uorescent staining for each chromosome showed a large number
f complex alterations in the chromosome complement of breast
ancer cell lines [18] (http://old-www.path.cam.ac.uk/∼paweﬁsh/
ndex.html). A study of HER2 ampliﬁed tumors showed increased
ains at 1q, 8q, 20q and losses at 18q, 13q, and 3p [19]. Comparative
enomic Hybridization (CGH) of 89 breast cancer tumors detected
requent gains at 1q, 8q, 11q, and 16p and losses at 4q, 5q, 6q, 8p, and
4q [20]. CGH was used to examine the chromosome complement
f 51 breast cancer cell lines and 145 primary breast cancer tumors
howed similar genetic changes in the cell lines and tumor sam-
les with some differences: losses in 5q and losses in chromosome
8 [21]. These studies showed that the chromosomal locations of
he reference genes need to be carefully considered and the assays
ave to be tested to ensure that the reference genes have not been
peciﬁcally ampliﬁed or deleted.
Suitable reference materials are needed for the new generation
f nucleic acid measurement methods for cancer that are now being
mplemented in clinical laboratories [22]. This report describes
he development of NIST SRM 2373 from ﬁve human breast can-
er cell lines with different degrees of ampliﬁcation of the HER2
ene. Assays were developed for HER2 and reference genes that are
ocated at different chromosomal regions that are not frequently
utated in cancer. The use of reference genes that are not located
n chromosome 17 (where the HER2 gene is located) allows the
etection of HER2 ampliﬁcation, due to the occurrence of chromo-
ome 17 polysomy [23]. The copy numbers of the HER2 gene and
elected reference genes were measured using both qPCR and dPCR
nd used to calculate the ratio of HER2 ampliﬁcation.
. Methods
.1. Breast cancer cell lines
DNA samples from ﬁve human breast cancer cell lines, SK-BR-
, MDA-MB-231, MDA-MB-361, MDA-MB-453, and BT-474, which
ere used to prepare components A, B, C, D, and E, respectively.
he cell lines were obtained from American Type Culture Col-
ection (ATCC, Manassas, VA) as frozen stocks and cultured in
he NIST laboratory using standard cell culture methods. MDA-
B-231, MDA-MB-361, and MDA-MB-453 cells were cultured in
eibovitz’s L-15 Medium (ATCC # 30-2008) supplemented with 10%
etal bovine serum (FBS, Gibco # 10437-028, except MDA-MB-361
here 20% FBS was used) at 37 ◦C in an air atmosphere without
dded CO2. SK-BR-3 cells were grown in the McCoy’s 5A modiﬁed
edium (ATCC # 30-2007) supplemented with 10% FBS at 37 ◦C in(chr22:41973682–41973704)
a humidiﬁed (5% CO2, 95% air) atmosphere. BT-474 cells were cul-
tured in the Hybri-Care Medium (ATCC # 46-X) supplemented with
1.5 g/L sodium bicarbonate and 10% FBS at 37 ◦C in a humidiﬁed (5%
CO2, 95% air) atmosphere.
2.2. Scale-up of DNA extraction and puriﬁcation
Large batches of cells were prepared from each cell line for
DNA extraction. The cells were sub-cultured for 4 to 5 passages,
and harvested when they reached ∼90% conﬂuence in ten T-175
cell culture ﬂasks. The culture medium was removed, the cells
were washed twice with Dulbecco’s Phosphate Buffered Saline
(DPBS), and the cells were treated with 0.25% (w/v) trypsin in
0.53 mM EDTA solution (Life Technologies, Grand Island, NY). Large
scale DNA extraction was  accomplished using Zymo Quick-gDNATM
midiPrep kits (Zymo, Irvine, CA). After the initial extraction, the
samples were pre-treated with bovine pancreatic ribonuclease A
before re-extraction. All puriﬁed genomic DNA samples were dis-
solved or eluted in 10 mmol/L Tris, 0.1 mmol/L EDTA, pH 8.0 buffer
(TE−4) and stored at 4 ◦C.
2.3. Cell line genotyping
The ﬁve breast cancer cell lines were genotyped upon receipt
from ATCC and after expansion using the AmpFLSTR Identiﬁler
Plus PCR Ampliﬁcation Kit (Life Technologies Cat# 4427368) on a
3500xl Genetic Analyzer with a 36-cm capillary array and POP-4
polymer (Life Technologies). PCR ampliﬁcation was carried out in
a total 12.5 L reaction volume (1/2 reactions) with 1 L of puri-
ﬁed genomic DNA (1.0 ng/L) on GeneAmp PCR System 9700 Cycler
(Life Technologies) for 28 cycles according to the conditions spec-
iﬁed by the manufacturer. Fifteen short tandem repeat (STR) loci
with Amelogenin (sex-typing marker) were co-ampliﬁed in a single
tube. After the reaction, 0.5 L of GeneScan 600 LIZ Size Standard
v2.0 and 8.5 L Hi-Di Formamide (Life Technologies) were added to
1 L of the PCR product or allelic ladder for a total volume of 10 L.
The samples were analyzed on the 24-capillary 3500xl Genetic Ana-
lyzer without prior denaturation of samples. Samples were injected
electrokinetically for 15 s at 1.2 kV. The STR alleles were then sep-
arated at 15 kV at a run temperature of 60 ◦C. Data from the 3500xl
was analyzed using GeneMapper ID-X software (version 1.3; Life
Technologies).
2.4. Preparation of DNA samples
The concentrated DNA stock solutions prepared from the cell
lines were diluted to an approximate concentration of 20–25 ng/L
(based on absorbance at 260 nm)  in TE−4. The individual DNA
solutions (approximately 45 mL)  were placed in 100 mL beakers
(polytetraﬂuoroethylene, VWR#89026-012) containing a polyte-
traﬂuoroethylene magnetic stir bar. The beaker and stir bar had
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een pre-treated with 10% bleach for 1 h, and then rinsed several
imes with sterile water and ﬁnally with ethanol. The beakers and
tir bars were then autoclaved (dry cycle) at 121 ◦C for 1 h. The
NA solutions were gently stirred for 3–4 h in a sterile laminar ﬂow
ood before dispensing. Samples (110 L) were pipetted into sterile
.5 mL  Sarstedt polypropylene tubes (#72.730.105, VWR  #10193-
60). The samples were stored in the dark at 4 ◦C.
The molecular mass and integrity of the DNA were assessed
sing gel electrophoresis (Cambrex Bio Science Rockland, Inc.,
ockland, ME). The gel was loaded with 2 L of each component
ith loading buffer; and the FlashGel DNA Marker was  used as a
olecular weight indicator. The gel was electrophoresed for about
 min  at 250 V.
.5. HER2 assay design and PCR conditions
The minimum information for publication of quantitative real-
ime PCR experiments (MIQE) [24] and for digital PCR experiments
25] guidelines were followed during the assay development and
or the measurements of the samples. The sequences of the oligonu-
leotide primers for HER2 and reference genes are shown in Table 1.
rimers were obtained from Life Technologies (Carlsbad, CA) or
DT (Coralville, Iowa) and were gel puriﬁed. All oligonucleotide
equences were designed with Primer3 (http://frodo.wi.mit.edu/
 or Primer Express (Version 3.0.1, Life Technologies) and checked
or speciﬁcity using BLAST searches of NCBI Nucleotide database.
CR was performed on a Veriti Thermal cycler (Applied Biosys-
ems, Waltham, MA)  in a total reaction volume of 20 L, containing
.1 ng linearized HER2 plasmid (for HER2 primers only) or 1 ng of
enomic DNA, 0.4 mol/L each primer, 0.2 mmol/L each deoxynu-
leotide triphosphate, and 0.5 U of Taq DNA polymerase in 1× PCR
uffer. All reagents were obtained from Roche Diagnostics (Pleasan-
on, CA). Non-template control samples were also run consisting of
E−4 buffer instead of the DNA samples. The following PCR cycling
onditions were used: an initial denaturation step of 1 min  at 95 ◦C,
ollowed by 35 cycles of 15 s at 95 ◦C, 20 s at 60 ◦C, and 15 s at 72 ◦C,
ith a ﬁnal extension step for 10 min  at 72 ◦C. The product of PCR
mpliﬁcation was monitored by electrophoretic separation on a
lashGel system.
.6. HER2 calibration
The plasmid pORF9-hERBB2 containing the full length of HER2
DNA was purchased from Invivogen (San Diego, CA). The construct
rame and the cDNA sequence were veriﬁed by restriction enzyme
nalysis and DNA sequencing. One microgram of HER2 plasmid was
inearized by 20 units of the restriction enzyme NotI (New England
iolabs, Ipswich, MA)  treatment in a 50 L reaction at 37 ◦C for
 h. The linearized HER2 plasmid was puriﬁed using QIAEX II Gel
xtraction Kit (Qiagen, Valencia, CA) and was eluted in TE−4, then
he DNA concentrations were quantitated by OD260 measurements.
 more sensitive Quant-iT PicoGreen dsDNA assay (Life Technolo-
ies, Grand Island, NY) was also used to quantitate the DNA samples,
ccording to the supplier’s protocol (BioTek Synergy MX,  Winooski,
T). Component A of SRM 2372 (2372-A), used for calibration of
hese assays, was derived from a single male donor [26].
The copy number of HER2 plasmid was calculated through the
ollowing formula:
opy number = 6.022 × 1023 × [Quantity]
molecular weight
he HER2 plasmid has 6780 bp (HER2 cDNA size is 3768 bp) result-
ng a molecular weight (MW)  of approximately 4,190,000 Da. One
opy of the HER2 cDNA equals 6.96 × 10−18 g of HER2 plasmid. For
enomic DNA, the assumption used was that one genome copy
s approximately 3 × 109 bp, with a resultant molecular mass ofand Quantiﬁcation 8 (2016) 1–8 3
approximately 3 pg, and therefore, 1 ng of human genomic DNA
would have approximately 333 copies of a single copy gene [27].
The HER2 copy number of 2372-A was  conﬁrmed using a lin-
earized HER2 plasmid with the calibration curve method. A dilution
curve was  constructed using ﬁve serial dilutions, in triplicate, of
2372-A ranging from 0.3 ng to 30 ng (100 to 10,000 haploid genome
copies) per reaction. A calibration curve using the HER2 plasmid
was constructed using ﬁve serial dilutions ranging from 0.696 fg to
6.96 pg (100 to 1,000,000 HER2 copies) per reaction. Each dilution
sample was  run 4 times. Analysis was  performed with SDS software
v2.4 (ABI) using a manual threshold of 0.2 and an automatic base-
line setting. The genomic HER2 gene copy number of 2 per diploid
genome in 2372-A was  conﬁrmed using this method.
2.7. Quantiﬁcation of gene copy number using SYBR Green qPCR
Each PCR reaction has a ﬁnal volume of 20 L: 10 L 2× SYBR
Green qPCR Supermix (LifeTechnologies), 0.2 L 5 mol/L ROX,
0.4 L 10 mol/L primer pair for HER2 or the reference genes, 5.4 L
water, and 4 L DNA template or non-template control. In each
96 well plate, half of the plate contained a calibration curve using
2372-A for HER2 (and three of the reference genes) with serial dilu-
tions (5-fold) resulting in approximately (4, 0.8, 0.16, and 0.032)
ng/L. The other half of the plate had one of the ﬁve breast cancer
cell line components. Assays for the reference genes in the compo-
nents were done at approximately (4, 0.8, 0.16, and 0.032) ng/L.
Assays for the HER2 copy number measurements of components B
and D were done at concentrations of approximately (4, 0.8, 0.16,
and 0.032) ng/L. Assays for the HER2 copy numbers of components
A, C, and E, were done at (0.8, 0.16, 0.032, and 0.0064) ng/L (due
to the high HER2 ampliﬁcation). All of the samples were measured
in triplicate. Fresh dilutions were prepared for the 2372-A calibrant
and the HER2 standard components each day.
Thermal cycling conditions for the ABI 7500 Real Time PCR sys-
tems are as follows: 50 ◦C for 2 min  (UDG incubation), 95 ◦C for
10 min, followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 60 s.
Melting curve analysis is performed from 60 ◦C to 95 ◦C. The dissoci-
ation curve of PCR products appears as a single peak, indicating the
ampliﬁed genes have similar sequences (G + C content) and there
was no evidence of nonspeciﬁc binding of primers. For each plate,
a calibration curve was constructed for each target gene (HER2
and three reference genes) using the logarithm of the initial copy
number of the 2372-A calibrant plotted along the X-axis and their
respective Cq values plotted along the Y-axis. The copy number
of HER2 and reference genes in 2372-A was calculated based on
the assumption that 2372-A has a DNA concentration of 57 ng/L
(information value from the SRM 2372 certiﬁcate of analysis, http://
www.nist.gov/srm/) and that 1 ng of 2372-A contains 333 copies
of HER2 and the reference genes. The equation and linear regres-
sion line for each target was  calculated using the following formula
Cq = m × log (copy number) + b.
A dilution curve similar to the calibration curve was  constructed
for each target of each SRM 2373 component. The efﬁciency of the
qPCR ampliﬁcation was assessed using the equation:
efﬁciency = (10(−1/m) − 1) × 100%
Inhibitors in the template DNA will reduce the efﬁciency and
increase the slope of the standard curve.
2.8. Quantiﬁcation of gene copy numbers using chamber dPCRThe chamber dPCR reactions were run on a BioMark platform
(Fluidigm, San Francisco, CA). The PCR reactions consisted of 1×
TaqMan Universal PCR Master Mix, No AmpErase UNG  (Life Tech-
nologies), 1× GE sample loading reagent (Fluidigm), with ﬁnal
4 H.-J. He et al. / Biomolecular Detection and Quantiﬁcation 8 (2016) 1–8
Table 2
TaqMan ﬂuorescent probe sequences.
Probe name Sequence 5′ Label 3′ Quencher
HER2-2 (BHQ) ACCCAGCTCTTTGAGGACAACTATGC FAM BHQ-1
EIF5B-P TTCAGCCTTCTCTTCTCATGCAGTTGTCAG FAM BHQ-1
RPS27A-P TTTGTCTACCACTTGCAAAGCTGGCCTTT FAM BHQ-1
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HQ-1TM (Black hole quencher) and FAM labeled probes were obtained from Biosea
oncentrations of 900 nmol/L primer and 250 nmol/L probe. The
oncentration of DNA molecules in the ampliﬁcation reaction mix
as adjusted so that there were 200–500 positive chambers in
 770 chamber/panel. The sequence information of primers and
robes are shown in Tables 1 and 2. Approximately 20 ng of
enomic DNA was applied in each 20 L reaction except for HER2
arget in SRM 2373 component A, C and E, where 4 ng of genomic
NA was applied (due to high HER2 ampliﬁcation). Then 4 L reac-
ion mixtures were loaded to each well on the array.
The PCR reactions were loaded into a 48.770 Digital Array
36,960 reactions per run), a 37K quantitative dPCR integrated ﬂu-
dic circuits (IFCs) chip which divides each sample well into 770
hambers. The ﬂuorescent signal for each reaction chamber was
ead after every cycle of ampliﬁcation. Thermal cycling was as fol-
ows: 95 ◦C for 10 min, and 60 cycles of 94 ◦C for 30 s and 60 ◦C for
 min, with ﬂuorescence measured at the end of the 60 ◦C step.
The number of positive chambers containing >1 DNA target
olecule were used to estimate the total number of targets per
eaction using Poisson statistics. The Fluidigm Digital PCR Analysis
ool was used to determine the count of positive chambers in each
anel of each 37K chip. The HER2 and three reference genes nom-
nal concentrations were calculated for each component using the
quation (Copies/ L):
DNA] = −ln (1 − (Number positive chambers/770))
0.85 × 10−3L
,
here 0.85 nL is the nominal chamber volume stated by the manu-
acturer. Two samples were measured using 3–6 replicates of each
arget gene for each component. Four 48.770 arrays were used over
our days. The copy number ratios (HER2 divided by the selected
eference gene) were then calculated.
.9. Quantiﬁcation of gene copy number using droplet dPCR
The Bio-Rad QX100 droplet digital PCR system which consists
f two components: the QX100 droplet generator and the QX100
roplet reader were used. The droplet generator utilizes microﬂu-
dics to partition samples randomly into approximately 20,000
anoliter-sized droplets. The TaqMan PCR reaction mixture con-
ists of 1× Droplet dPCR Supermix for probes (Bio-Rad, Hercules,
A), 900 nmol/L primers, and 250 nmol/L probe (ﬁnal concentra-
ions) and genomic DNA template or non-template control in a total
olume of 25 L. The copy number of HER2, EIF5B, DCK, and RPS27A
as determined in the ﬁve components (primers and probes in
ables 1 and 2). Approximately 20 ng of genomic DNA was applied
n each reaction except for HER2 target in SRM 2373 component A,
 and E, where 4 ng of genomic DNA was applied.
Twenty microliters out of the 25 L droplet dPCR reaction
ixture was transferred to the droplet generator DG8 cartridge
Bio-Rad). Droplet generation oil (70 L, Bio-Rad) was added into
he oil well for each channel. The wells were covered with a droplet
enerator DG8 gasket, and the cartridge was placed into the droplet
enerator (Bio-Rad). After the droplet generation was complete,
he droplets were then carefully transferred to a 96-well PCR plate
sing an 8-channel pipette. The plate was covered with foil using a
eat sealer (Eppendorf, Hamburg, Germany) and then was placedFAM BHQ-1
echnologies (Novato, CA).
on an Applied Biosystems Veriti 96-well thermal cycler. The fol-
lowing thermal cycling conditions were used: 95 ◦C for 10 min,
followed by 40 cycles of 94 ◦C for 30 s and 60 ◦C for 1 min, then
98 ◦C for 10 min, temperature ramp rate at 50% (3 ◦C/s). After PCR,
the 96-well PCR plate was loaded onto the QX100 droplet digi-
tal reader (Bio-Rad), which automatically reads the droplets from
each well of the plate. PCR-positive and PCR-negative droplets are
counted to provide nominal quantiﬁcation of target DNA using the
equation (Copies/ L):
[DNA] = −ln(1 − (Number positive droplets/Number of counted droplets))
(0.91 × 10−3L)
where 0.91 nL is the nominal droplet volume speciﬁed by the
manufacturer. As described below 10 samples were measured in
triplicate for the HER2 and reference genes. The stock concentration
was obtained by multiplying the dilution factor by the measured
concentration.
2.10. Homogeneity and stability measurements
To determine homogeneity, ten sets of the ﬁve components
(total of 50 vials) were selected for qPCR and dPCR measurements
(done as described above using two  different ABI 7500 qPCR instru-
ments and a Bio-Rad QX100 dPCR instrument by two operators).
The vial numbers (order of ﬁlling) selected were: 30, 60, 90, 120,
150, 180, 210, 240, 270, and 300.
To further evaluate the effects of different operators and qPCR
measurement platforms, two sets of the ﬁve components (vial num-
bers 213 and 245) were randomly selected and evaluated using
ABI 7900 and ABI ViiA7 instruments (both in a 96-well format)
according to the above protocol except for using SYBRGreen PCR
Master Mix  (Catalog# 4309155, Life Technologies). These samples
were analyzed by a total of ﬁve different operators using four qPCR
instruments at the NIST laboratories.
Another single independent component set was  analyzed using
a ViiA7 (384-well format) instrument. For this instrument the copy
number was  determined using a TaqMan HER2 copy number assay
(Assay ID: Hs00783404 cn, Life Technologies) for HER2 gene, and
using TaqMan Copy Number Reference Assay of RNase P (Catalog#:
4403326, Life Technologies) and RPS27A (Assay ID: Hs03422139 cn,
Life Technologies) as reference genes. Data from these experiments
were utilized in the combined HER2 ratio and uncertainty analysis,
described below.
Stability measurements were done using the master stock sam-
ple used to prepare the standards stored at 4 ◦C in the dark for
different periods of time (up to 856 days) using the droplet dPCR
method. Digital PCR measurements of HER2 and the reference gene,
RPS27A, were done in triplicate on the master stock sample to deter-
mine any trends in the values with time within the uncertainty of
the measurements.
2.11. Analysis of qPCR and dPCR data for a combined HER2 ratio
and uncertainty analysis
This section provides an overview of the modeling methods that
were used to produce certiﬁed values for the HER2 copy number
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atios and to determine the uncertainties in SRM 2373 ratio values.
 more detailed description of the analysis and model can be found
n the Supplemental Materials section. SRM 2373 contains certi-
ed values for the geometric average copy number ratio between
ER2 and suitable reference genes. Let Ratiogs = HER2s/Refgs where
ER2s is the copy number of HER2 in component s and Refgs is the
opy number of reference gene g in component s . The ratios, rather
han the HER2 copy number itself, were certiﬁed due to uncertainty
n the true DNA copy number of the calibrator used for the qPCR
easurements and the true chamber and droplet volumes. These
ssues cancel out when taking the ratio between copy numbers of
wo genes from the same sample.
The qPCR instrument measures the ﬂuorescence intensity of the
eaction to detect the cycle number when the intensity reaches the
hreshold value. This value will depend upon not only the number of
arget DNA copies initially added to the reaction but also other fac-
ors speciﬁc to the particular PCR reaction, including the sequence
f the target amplicon, the primer sequences, binding efﬁciencies,
he polymerase used, and the SYBR Green dye binding. In order
o compensate for these differences in the PCR reactions of HER2
nd the reference genes we chose to use 2372-A, puriﬁed from the
hite blood cells of from a single male donor, as the human genomic
NA calibrator. Other genomic DNA samples that have normal copy
umbers of HER2 and the selected reference genes could also be
sed as a calibrator. To normalize for the differences in the ﬂuo-
escence signal development of the HER2 and the reference genes
CR reactions, a calibration curve for 2372-A was  always run on
he same plate as the SRM 2373 samples. The copy number ratio
etween HER2 and reference gene g in sample s from plate p and
nitial gene copy number, is given by:
atiogsp =
RHER2,sp/Rgsp
RHER2,2372,p/Rg,2372,p
,
here RHER2,2372,p and Rg,2372,p correspond to the initial abundance
f HER2 and reference gene g respectively, in a sample of 2372-A
n plate p. This step corrects for the differences in the development
f ﬂuorescence signal between the different PCR reactions for HER2
nd the reference genes.
The qPCR data as reported as pairs of dilution factor and corre-
ponding Cq values resulting from a single dilution experiment,
pplied to a single targeted gene in a single biological sample
etween HER2 and a given reference gene in a single replicate of
 given component. A linear regression model is ﬁt to these data
nd used to estimate the abundance of gene g in sample s from
late p, Rgsp. Uncertainty and bias in slope estimates derived from
PCR data for a single gene in a single sample frequently cause the
rdinary least squares analysis to perform poorly [28]. This may
e due to variability in the pipetting process to create the dilu-
ion series. To estimate and account for the variability around the
esired dilutions, all qPCR data (comprised of 6423 pairs of dilution
ractions and corresponding Cq values from 556 unique combina-
ions of target gene and dilution series) were combined into a single
ayesian analysis, which was evaluated via Markov Chain Monte
arlo (MCMC) (Supplementary Materials Section).
For dPCR experiments, the abundance of gene g in sample s
rom plate p is estimated from the proportion of chambers or
roplets in which no copies were detected. Suppose that out of Ngsp
otal droplets/chambers, there were Ygsp droplets/chambers within
hich no copies of gene g were detected. The abundance of gene
 in sample s from plate p is estimated by modeling Ygsp as follow-
ng a binomial distribution with Ngsp observations and probability
−gsp where gsp is the average number of copies of gene g per
roplet/chamber in sample s on plate p. The relationship between
he average number of copies per droplet/chamber and the prob-
bility of not observing any copies in a given droplet comes fromand Quantiﬁcation 8 (2016) 1–8 5
assuming that gene copies within droplets are distributed accord-
ing to the Poisson distribution, for which
Pr (no copies in droplets) = e−average # of copies per droplet.
The copy number ratio between HER2 and reference gene g in sam-
ple s from plate p when evaluated using digital PCR, is then given
by Ratiogsp = HER2,sp/gsp.
The geometric average copy number ratio for each reference
gene in each component was  evaluated from the collection of
copy number ratios for individual replicates using a mixed effects
model that included random effects for combination of operator
and instrument, date, bottle and plate (i.e. a catch-all for random
errors other than those previously stated). To generalize the results
across a broader population of reference genes from which the cho-
sen reference genes were considered a representative sample (i.e.
those with similar copy number stability across biological samples),
the log copy number ratio for each reference gene in a given sam-
ple was  modeled as a random draw from a normal distribution with
unknown mean  = log (Ratios) and unknown standard deviation.
The posterior credible interval for Ratios is used to establish the
reported uncertainty for the certiﬁed copy number ratio in sample
s on the certiﬁcate of SRM 2373. The relative effect of each of these
variables is shown as the percentage of the largest source of vari-
ability that was the plate (catch all for the experimental setup of a
microplate) (Fig. 4).
3. Results and discussion
3.1. Breast cancer cell line and preparation of the standard
Cell lines are a renewable source of materials for developing
reference materials, but the products need to be extensively char-
acterized for each lot of materials. We  selected ﬁve breast cancer
cell lines with different HER2 copy number to make the reference
materials. The breast cancer cell lines used for these samples are fre-
quently used in research studies. These cancer cell lines and many
others, because of their importance to basic research and thera-
peutic screening, are now the subject of sequencing projects, such
as the Cancer Cell line Encyclopedia (http://www.broadinstitute.
org/ccle/home) and the Catalogue of Somatic Mutations in Cancer
(COSMIC, http://cancer.sanger.ac.uk/cell lines).
The identities of the cell lines were conﬁrmed using STR geno-
typing before and after scale-up of the production of the standard.
The STR proﬁles from the genotyping were the same for the DNA
samples prepared before and after scale-up (Supplemental Table
1). The STR proﬁles matched the nine loci STR proﬁle provided by
ATCC.
The cell lines were harvested for DNA extraction after no more
than eight passages of the initial cell stocks. The ratio between
absorbance at 260 nm and 280 nm (OD260:OD280) provides an esti-
mate of the purity of the nucleic acid. A ratio between absorbance at
260 nm and 230 nm (OD260:OD280) that is lower than 2 can be due
to contamination by phenol, thiocyanates, and other organic com-
pounds, whereas absorbance at 330 nm (OD330) is usually caused
by light scattering and indicates the presence of particulate mat-
ter. The results shown in Supplemental Table 2 indicate the high
quality of the DNA samples. Gel electrophoresis did not show any
indication of low molecular weight contaminants (Supplemental
Fig. 1).
The packaging, storage conditions, and characterization of
SRM 2373 were greatly aided by the experience gained from
development of SRM 2372 [26]. The sample volume of 110 L
(approximately 2 g of DNA) per tube provides enough material for
HER2 copy number assays, including next-generation sequencing.
The samples are stored at 4 ◦C, protected from light.
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Fig. 1. A comparison of the average ratios of HER2 copies with respect to three
reference genes for droplet dPCR and chamber dPCR for each component of SRM H.-J. He et al. / Biomolecular Dete
.2. qPCR assays and copy number measurements
The MIQE guidelines were followed to ensure the reliable
eporting of the assay conditions [24]. In addition to reporting
he relevant information about the assay design and conditions,
he qPCR assays must be checked for speciﬁcity and efﬁciency
29]. Speciﬁcity was determined by a single PCR amplicon being
roduced. BLAST searches (http://blast.ncbi.nlm.nih.gov/Blast.cgi)
ere done to ensure that the primers and probes for the dPCR
ssays only bind to the target sequences in the human genome.
unning the PCR products on a gel to ensure a single band and
elting curve analysis of the PCR products after SYBR Green PCR
mpliﬁcation were also done to conﬁrm the assay speciﬁcity.
2372-A, genomic DNA from a single male donor, was used as
he calibrant for the qPCR measurements and to conﬁrm the dPCR
ssays. For each qPCR measurement on a 96 well plate a calibration
urve was done using SRM 2372 and a dilution curve was  made
sing the SRM 2373 components.
SYBR Green single-analyte assays were used for the qPCR reac-
ions because of the higher precision and lower coefﬁcient of
ariation compared to TaqMan and probe hybridization assays [30].
he HER2 gene has a total length of 40,523 bp. As shown in Supple-
ental Table 3, ﬁve primer pairs were designed to span the HER2
ene. The amplicon for HER2-1 primer set is located in intron 4, and
mplicons of HER2-2, HER2-3, and HER2-5 primer sets are located
n exons 7, 13, and 21, respectively, while the amplicon for HER2-4
rimer set spans the regions of exon 14 and exon 15. PCR was  per-
ormed using either 2372-A or HER2 cDNA plasmid as templates.
he results of the gel electrophoresis of the PCR products are shown
upplemental Fig. 2. The PCR product bands using genomic DNA
ave the expected amplicon sizes. When using the HER2 cDNA plas-
id  as a template (panel B of Supplemental Fig. 2), no amplicon
as detected from HER2-1 primers, because there are no introns
resent in the HER2 cDNA plasmid and the amplicon from primer
et HER2-4 produced the expected shorter PCR fragment due to the
limination of the intron region between exon 14 and exon 15 in
he HER2 cDNA plasmid.
The SYBR Green based qPCR assays were done using the ﬁve
ER2 primer pairs. The ampliﬁcation efﬁciency of the qPCR reac-
ions were calculated based on the slopes of the calibration curves
nd the primer speciﬁcities were determined by the dissociation
urves and gel electrophoresis. All ﬁve HER2 primer pairs had sat-
sfactory ampliﬁcation efﬁciencies (within the range of 90–110%)
nd primer speciﬁcity indicated a single product using gel elec-
rophoresis and melting curve analysis. All of the assays had high
fﬁciencies and speciﬁcities, however it was decided to use HER2-2
ssay for the extensive measurements of the HER2 copy number in
he components of SRM2373.
A linearized HER2 plasmid was used to conﬁrm the copy number
f HER2 in 2372-A. The linearized plasmid concentration was  deter-
ined by spectrophotometric analysis and PicoGreen assays. The
esults from absorbance and PicoGreen assays differed by approx-
mately 2.5% (results not shown). The HER2 plasmid was  used to
onstruct the calibration curve for the qPCR assays. The relation-
hip of the 2372-A copy number and HER2 plasmid copy number
ad a correlation coefﬁcient of 0.9924. This data conﬁrmed that
372-A has a single HER2 copy number per haploid genome and
s a suitable calibrant for the HER2 gene copy measurements. The
ER2 and reference gene assays were run using the same sample
ilutions and on the same plate..3. Digital PCR measurements
Three TaqMan assays for the reference genes, EIF5B, RPS27A, and
CK were developed. The gene locations and primer sequences for2373. Error bars are 1 standard deviation, where N = 10 samples for the droplet dPCR
(ddPCR) and N = 3 samples for the chamber dPCR (cdPCR).
the reference genes are shown in Table 1 and the probes developed
are shown in Table 2 (used for the dPCR measurements).
Measurements using qPCR have been shown to be able to detect
gene copy number differences of 1.5 fold [31]. However, qPCR has
limitations such as PCR efﬁciency, which will change the Cq values
and the calculated fold differences [32]. dPCR can be considered an
end-point assay where each reaction is either positive or negative
and therefore differences in ampliﬁcation efﬁciencies are not as
critical as in qPCR measurements.
The calculations for DNA copies were evaluated using Poisson
sampling statistics with the assumption that the DNA molecules
were partitioning independently from each other into the individ-
ual droplets or chambers. To calculate the concentration of DNA,
the sizes or the numbers of droplets or chambers must be accu-
rately known. The uncertainty of the volume measurements of the
droplets generated in the Bio-Rad instrument has not yet been
fully investigated. The National Measurement Institute (Australia)
has measured the volume of droplets [33] and NIST is currently
characterizing the volumes formed under different conditions. A
comparison of ratios of HER2 to the reference genes for the droplet
dPCR and the chamber dPCR instruments is shown in Fig. 1. The two
instruments yielded very similar HER2 gene ratio values for the ﬁve
components.
3.4. Agreement of qPCR and dPCR measurements
The results of the different reference genes for the copy number
(copies/L) for the different components determined using qPCR
and dPCR are shown in Fig. 2 (data in Supplemental Tables 3 and
4). The results show that the reference genes are consistent for
each of the components and also consistent between the two mea-
surement methods. The assays for HER2 and the reference genes
were validated for each component. Different reference genes were
used for the qPCR assays and dPCR measurements, and they gave
similar results (Fig. 2). The agreement between results of the two
methods is encouraging, given that the two  methods use different
assumptions for the ﬁnal calculation of the copy number.
The digital PCR calculation requires the assumption of the
independent partitioning of DNA fragments and also the accurate
determination of the volume of the droplets (or chambers). The ﬁve
components of SRM 2373 did not show an increase in HER2 copy
number after digestion of the DNA with the restriction enzymes
MseI or RsaI (results not shown), indicating that the HER2 gene
H.-J. He et al. / Biomolecular Detection and Quantiﬁcation 8 (2016) 1–8 7
Fig. 2. Comparison of copy number of the reference genes using qPCR (top) and
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Fig. 3. Stability studies of SRM 2373. Copy number of the HER2 copy number (top,
HER2 copy concentration in SRM 2373 components) and ratios of the HER2 copy
number to RPS27A reference gene (bottom). Individual samples from the master
stock sample used to prepare the standards stored using the same conditions as the
samples, measurements in triplicate.
Fig. 4. The results from the random effects model were broken down into the plate
(microplate experimental setup), the machine (instruments) and operator, the date
(of analysis), and the vial (sample). In the boxplot for each effect, the bold horizontal
line depicts the median of the MCMC  samples, the horizontal lines at the top and
bottom of the box depict the 75% and 25% quantiles, respectively; and the whiskers
and individual circles characterize the tails of the MCMC sampling distribution. ThedPCR (bottom) and the indicated reference genes (gene copy concentration in SRM
373 components). Error bars are 1 standard deviation, where N = 10 independent
amples for the qPCR and dPCR measurements.
ragments were partitioning independently of each other into the
roplets.
.5. Calculation of the HER2 to reference gene copy number ratios
A NIST certiﬁed value is a value for which NIST has the highest
onﬁdence in its accuracy in that all known or suspected sources
f bias have been investigated or accounted for by NIST [34]. The
ertiﬁed ratios for HER2 to the reference genes based on all of the
ata along with the calculated 95% conﬁdence interval are listed
n Table 3. The prediction intervals are the approximate range of
alues that NIST would reasonably expect upon the next single,
ndependent measurement of the HER2 copy number ratio approx-
mately 68% of the time, based on our measurements.
.6. Homogeneity and stability studies
The analysis of ten sets of samples (out of approximately 350)
istributed throughout the dispensing order were analyzed. There
ere no signiﬁcant trends in the HER2 copy number values that
ere detectable within the detection limits of the assays. The HER2
opy number or the ratio of HER2 to the reference gene RPS27A did
ot show any signiﬁcant changes in any of the ﬁve components for
eriods of time up to 856 days, the last storage time analyzed (given
he uncertainty of the measurements) (Fig. 3).combined data from the effects data from qPCR (using ﬁve instruments and ﬁve
operators) and dPCR (using two instruments and two operators) were analyzed
using the model detailed in Supplemental materials.
3.7. Effect of variables on the measurement uncertaintyThe results from the random effects model were broken down
into the plate (catch all microplate experimental setup), the
machine (instruments) and operator, the date (of analysis), and the
vial (sample) (Fig. 4). This analysis suggests that the largest compo-
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Table 3
The certiﬁed values, ratios of HER2 copies to the reference genes, 95% uncertainty interval and 68% prediction interval.
Component Cell line Ratio 95% uncertainty interval 68% prediction interval
A SK-BR-3 9.7 8.7–10.7 5.8–20.8
B  MDA-MB-231 1.3 1.1–1.5 0.6–1.9
C  MDA-MB-361 6.4 5.7–7.1 4.8–14.2
D  MDA-MB-453 2.9 2.6–3.2 1.4–7.2
E  BT-474 17.7 15.9–19.5 11.7–45.3
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format for DNA copy number quantiﬁcation, Anal. Chem. 84 (2012)
1003–1011.
[34] W.  May  et al., Standard Reference Materials® , Deﬁnitions of Terms and Modeshe uncertainty intervals characterize the uncertainty in the long-run averages of m
he  distribution of individual observations is expected to exhibit substantially greate
ntervals.
ent of variability was in the plate category, which is the catch-all
andom error associated with setting up a microplate between dif-
erent measurements. The variability attributed to the combination
f instrument and operator, the date or the vial were moderate.
he vertical and horizontal lines in Fig. 4 display the 95% posterior
redible intervals and posterior expectations, respectively, for the
tandard deviations of these random effects from the combined
nalysis of the data from qPCR (using 5 instruments) and dPCR
using two instruments).
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